p16 expression in sentinel nodes with metastatic breast carcinoma: Evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis

Human Pathology

Volumn 35, Issue 12, 2004, Pages 1524-1530

  Singh, Meenakshi ^a,b   Parnes, Mikelle B ^a   Spoelstra, Nicole ^a   Bleile, Michelle J ^a   Robinson, William A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

AN; AND; axillary node; axillary node dissection; breast carcinoma metastasis; DAB; DCIS; diaminobenzidine; ductal carcinoma in situ; ER; estrogen receptor; MBC; metastatic breast carcinoma; p16; PI; proliferation index; sentinel lymph node

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P16;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST DUCT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; METASTASIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 10944256605     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.09.013     Document Type: Article

References (21)

1. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 349:2003;546-553
2. Greene F.L., Page D.L., Fleming I.D.,, et al. AJCC Cancer Staging Manual. (ed 6):2002;221-240 Springer, New York
3. Turner R.R., Chu K.U., Qi K., et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 89:2000;574-581
4. Chu K.U., Turner R.R., Hansen N.M., et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection. Ann Surg. 229:1999;536-541
5. Degnim A.C., Griffith K.A., Sabel M.S., et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma. Cancer. 98:2003;2307-2315
6. Hwang R.F., Krishnamurthy S., Hunt K.K., et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 10:2003;248-254
7. Robinson W., Miller T., Harrold E., et al. The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma Res. 13:2003;231-238
8. Kubo A., Kaye F. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway. J Natl Cancer Inst. 93:2001;415-417
9. Belinsky S., Nikula K., Palmisano W., et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci. 95:1998;11891-11896
10. Prowse A., Schultz D., Guo S., et al. Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet. 40:2003;e102
11. Silva J., Silva J., Domingues G., et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol. 199:2003;289-297
12. Schoppmann S., Schindl M., Bayer G., et al. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer. 104:2003;677-682
13. Bisogna M., Calvano J., Ho G., et al. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genet Cytogen. 125:2001;131-138
14. Tsuda H., Yamamoto K., Inoue T., et al. The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer. 82:2000;675-682
15. Geradts J., Ingram C.D. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol. 13:2000;945-953
16. Dublin E.A., Patel N.K., Gillett C.E., et al. Retinoblastoma and p16 proteins in mammary carcinoma Their relationship to cyclin D1 and histopathological parameters. Int J Cancer. 79:1998;71-75
17. Han S., Ahn S.H., Park K., et al. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat. 70:2001;205-212
18. Hui R., Macmillan R.D., Kenny F.S., et al. INK4a gene expression and methylation in primary breast cancer Overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 6:2000;2777-2787
19. Saegusa M., Machida B.D., Okayasu I. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer. 92:2001;1177-1189
20. Cameron R.I., Maxwell P., Jenkins D., et al. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology. 41:2002;313-321
21. Milde-Langosch K., Riethdorf L., Bamberger A., et al. P16/MTS1 and pRb expression in endometrial carcinomas. Virchows Arch. 434:1999;23-28